PRELUDE THERAPEUTICS INC (PRLD)
US74065P1012 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A -100.00% | N/A | N/A | N/A | N/A 211.29% | N/A 67.97% | N/A 61.27% | |||||||
| EBITDA YoY % growth | -14.83M | -27.73M -86.99% | -58.22M -109.95% | -112.82M -93.78% | -122.22M -8.33% | -131.108M -7.27% | N/A -15.27% | N/A -12.92% | N/A -8.79% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -14.98M | -28.11M -87.65% | -58.76M -109.04% | -113.74M -93.57% | -123.54M -8.62% | -132.277M -7.07% | N/A -12.93% | N/A -8.78% | N/A -1.17% | N/A -9.20% | N/A -0.28% | N/A 19.87% | N/A 69.62% | N/A 136.06% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -2.42 35.79% | -2.44 -0.83% | -2.03 16.80% | N/A 10.81% | N/A 15.63% | N/A 11.85% | N/A -3.79% | N/A 8.03% | N/A 34.92% | N/A 34.15% | N/A 70.37% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.48 -3.66% | -0.44 -4.43% | -0.43 5.76% | -0.44 -3.19% | -0.45 5.88% |
| Revenue Q2Q % growth | -100.00% | ||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -39.277M -5.08% | -40.438M -17.75% | -42.041M -13.12% | -42.657M -24.09% | -43.358M -10.39% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.43 4.44% | -0.48 | 0.05 | 10.65% |
| Q2 2024 Q2Q % growth | -0.46 14.81% | -0.44 | -0.02 | -4.88% |
| Q1 2024 Q2Q % growth | -0.42 27.59% | -0.49 | 0.07 | 15.10% |
| Q4 2023 Q2Q % growth | -0.46 23.33% | -0.50 | 0.04 | 7.96% |
| Q3 2023 Q2Q % growth | -0.45 28.57% | -0.59 | 0.14 | 24.24% |
| Q2 2023 Q2Q % growth | -0.54 6.90% | -0.65 | 0.11 | 16.41% |
| Q1 2023 Q2Q % growth | -0.58 7.94% | -0.70 | 0.12 | 16.99% |
| Q4 2022 Q2Q % growth | -0.60 15.49% | -0.64 | 0.04 | 6.33% |
| Q3 2022 Q2Q % growth | -0.63 4.55% | -0.65 | 0.02 | 2.89% |
| Q2 2022 Q2Q % growth | -0.58 | -0.62 | 0.04 | 6.78% |
| Q1 2022 Q2Q % growth | -0.63 -34.04% | -0.66 | 0.03 | 4.98% |
| Q4 2021 Q2Q % growth | -0.71 -57.78% | -0.70 | -0.01 | -1.99% |
| Q3 2021 Q2Q % growth | -0.66 87.43% | -0.64 | -0.02 | -3.53% |
| Q2 2021 Q2Q % growth | -0.58 | -0.50 | -0.08 | -15.11% |
| Q1 2021 Q2Q % growth | -0.47 | -0.43 | -0.04 | -8.68% |
| Q4 2020 Q2Q % growth | -0.45 | -0.48 | 0.03 | 5.63% |
| Q3 2020 Q2Q % growth | -5.25 | -0.44 | -4.81 | -1,096.99% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | -10.43% | 2.47% | 3.08% |
| Revenue | N/A | N/A | N/A | N/A |